The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Howlader, Nadia; Forjaz, Gonçalo; Mooradian, Meghan J.; Meza, Rafael; Kong, Chung Yin; Cronin, Kathleen A.; Mariotto, Angela B.; Lowy, Douglas R.; Feuer, Eric J.

doi:10.1056/nejmoa1916623

Cited by 999 publications

(759 citation statements)

References 36 publications

Supporting

Mentioning

723

Contrasting

Unclassified

Order By: Relevance

“…First line therapies that incorporates immunotherapy, either as a single modality or with chemotherapy, can be offered to significant part of NSCLC patients. These advances in lung cancer therapeutics, along with other causes, resulted in a decrease in population-level mortality from NSCLC in the United States from 2013 to 2016 [114]. Figure 5 provides and algorithm for treatment of patients with NSCLC.…”

Section: Discussionmentioning

confidence: 99%

First line Immunotherapy for Non-Small Cell Lung Cancer

2020

View full text Add to dashboard Cite

Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), with or without chemotherapy. The inclusion criteria differ between the various clinical trials, including the cut-off levels of PD-L1 expression on tumor cells, and the tumor histology (squamous or non-squamous). Patients with tumor expression levels of PD-L1 ≥ 50% are candidates for treatment with single agent Pembrolizumab or Atezolizumab. Patients with PD-L1 < 50% are candidates for immunotherapy with pembrolizumab as a single agent if PL-1 > 1%; immunotherapy doublet, Nivolumab and Ipilimumab, or single agent immunotherapy combined with chemotherapy. Here we review phase 3 clinical trials utilizing immunotherapy in the first line for treatment of NSCLC, including Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150.

show abstract

Section: Discussionmentioning

confidence: 99%

First line Immunotherapy for Non-Small Cell Lung Cancer

2020

View full text Add to dashboard Cite

show abstract

“…Lung cancer incidence and mortality in the United States have been on the decline, due in large part to a sharp reduction in tobacco use. 1 Results of a recent study have brought additional good news: For patients with non-small cell lung cancer (NSCLC), mortality is decreasing faster than incidence, 2 suggesting that the recent rise in the use of targeted therapies is having a very signi cant impact on overall survival. But work still needs to be done.…”

Section: Interviewmentioning

confidence: 99%

“…Moreover, in 12 patients with particularly large tumors (stage T3-T4), the pCR rate was 42%, with half of those patients seeing their tumor size reduced to stage T1 or less. 2 Importantly, median overall survival (OS) has not yet been reached, and 24 patients were still alive at 1 year. Additionally, 82.8% of patients who had surgery were free of disease recurrence at 1 year.…”

Section: Tremelimumab Durvalumab Combo Shows Promise For Certain Patmentioning

confidence: 99%

Optimizing Therapies For Patients With Lung Cancer

2020

Oncology

View full text Add to dashboard Cite

“…The utility of tumor genotyping is widely recognized at all stages of the clinical evaluation process in non-small-cell lung cancer (NSCLC) [1]. The deeper understanding of specific genomic alterations driving NSCLC development led to novel therapeutics with a dramatic impact on patients' outcomes [2]. Recently approved drugs will certainly have a further impact on outcomes in the near future.…”

Section: Introductionmentioning

confidence: 99%

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer

Gobbini

Swalduz

Levra

et al. 2020

Cancers

View full text Add to dashboard Cite

Tumor genomic profiling has a dramatic impact on the selection of targeted treatment and for the identification of resistance mechanisms at the time of progression. Solid tissue biopsies are sometimes challenging, and liquid biopsies are used as a non-invasive alternative when tissue is limiting. The clinical relevance of tumor genotyping through analysis of ctDNA is now widely recognized at all steps of the clinical evaluation process in metastatic non-small cell lung cancer (NSCLC) patients. ctDNA analysis through liquid biopsy has recently gained increasing attention as well in the management of early and locally advanced, not oncogene-addicted, NSCLC. Its potential applications in early disease detection and the response evaluation to radical treatments are promising. The aim of this review is to summarize the landscape of liquid biopsies in clinical practice and also to provide an overview of the potential perspectives of development focusing on early detection and screening, the assessment of minimal residual disease, and its potential role in predicting response to immunotherapy. In addition to available studies demonstrating the clinical relevance of liquid biopsies, there is a need for standardization and well-designed clinical trials to demonstrate its clinical utility.

show abstract

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Cited by 999 publications

References 36 publications

First line Immunotherapy for Non-Small Cell Lung Cancer

First line Immunotherapy for Non-Small Cell Lung Cancer

Optimizing Therapies For Patients With Lung Cancer

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About